<DOC>
	<DOCNO>NCT00328562</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness Iressa use short course high dose radiation therapy patient lung cancer .</brief_summary>
	<brief_title>ZD1839 With Hypofractionated Radiation Therapy With Immobilization Device Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>To estimate treatment-related esophageal , pulmonary , hematologic , toxicity patient non-small-cell lung cancer ( NSCLC ) receive ZD1839 hypofractionated thoracic radiotherapy ( RT ) . All estimate toxicity rate present correspond confidence interval use exact method . The method Atkinson Brown use due two-stage sampling ; method Conover use tumor response . To estimate tumor response rate treatment regimen identify effective RT dose level , define level associate best response rate . Estimates tumor response rate present correspond confidence interval use exact method Conover . Survival estimate Kaplan-Meier method .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically confirm non small cell lung cancer Stage IV need radiation therapy control symptoms Patients brain metastasis Unresectable medically inoperable Small cell lung cancer Previous thoracic radiation therapy Oxygendependent patient Forced expiratory volume 1 second ( FEV1 ) less 1.5 Patients active interstitial lung disease Patients underlie lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Advanced NSCLC</keyword>
	<keyword>Non-Small Cell Lung Carcinoma</keyword>
	<keyword>Stage IV NSCLC</keyword>
</DOC>